Pompeu Fabra University is a university in Barcelona, Catalonia, Spain. Founded in 1990, it is named after the Catalan philologist Pompeu Fabra. Currently , the University offers 22 undergraduate degrees, 25 official masters, and 9 PhD programs, as well as around 100 UPF masters. It is currently the only Spanish university to figure in the Times Higher Education top 200 ranking at position 164. Wikipedia.
University Pompeu Fabra | Date: 2017-07-26
The system comprising an internal unit (10) comprising two arrays of N transmitter and N receiver antennas (11R, 11 T) for transmitting a microwave signal(s) to one or more body tissues of a patient and for detecting a scattered microwave signal(s) by said one or more body tissues; feeding and multiplexing means (12) in connection with said N transmitter and N receiver antennas (11T, 11 R) and with an external computing unit (20) configured to receive said scattered microwave signal(s) and convert it/them into an image, wherein the feeding and multiplexing means (12) provide, under the control of a controller (21) of the external computing unit (20), a continuous sequential selection of different pairs of transmitter and receiver antennas (11T, 11 R) to perform the transmission of the microwave signal(s) and the detection of the scattered microwave signal(s).
University Pompeu Fabra | Date: 2017-03-29
The present invention belongs to the field of virology and is related to agents with antiviral activity against enveloped viruses, particularly anti-HIV and anti-HCV activity, and methods for the prevention of viral infection in a subject, in particular HIV and HCV infections. Agents according to the invention comprise a DNA-lipid conjugate forming a G-quadruplex structure.
University Pompeu Fabra | Date: 2017-10-11
Control of cancer progression by retinoblastoma phosphorylation. The invention provides a method based on the finding that phosphorylation of RB protein in the N-terminal domain, namely at Serine 249 and Threonine 252 of human RB, leads to a conformational change that makes RB insensitive to CDK inactivation, promoting a cell cycle delay that reduces cell proliferation in cancer cells. The method identifies as candidates to anticancer drugs those compounds that give rise to modifications analogous to those provoked by RB phosphorylation in the N-terminal domain, mainly increased affinity of RB for E2F, decreased transcription of E2F and/or decreased expression of E2F-dependent genes, increased RB binding to E2F-dependent promoters or decreased cell proliferation. The method can be also carried out measuring the expression of an indicator gene operatively linked to an E2F-dependent promoter. Expression vectors of mutated retinoblastoma proteins mimicking phosphorylation at the N-terminal domain are also provided for therapeutic use.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses ICT to integrate neuroscience data from around the world, to develop a unified multi-level understanding of the brain and diseases, and ultimately to emulate its computational capabilities. The goal is to catalyze a global collaborative effort. During the HBPs first Specific Grant Agreement (SGA1), the HBP Core Project will outline the basis for building and operating a tightly integrated Research Infrastructure, providing HBP researchers and the scientific Community with unique resources and capabilities. Partnering Projects will enable independent research groups to expand the capabilities of the HBP Platforms, in order to use them to address otherwise intractable problems in neuroscience, computing and medicine in the future. In addition, collaborations with other national, European and international initiatives will create synergies, maximizing returns on research investment. SGA1 covers the detailed steps that will be taken to move the HBP closer to achieving its ambitious Flagship Objectives.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: DRS-01-2015 | Award Amount: 6.73M | Year: 2017
In every disaster and crisis, incident time is the enemy, and getting accurate information about the scope, extent, and impact of the disaster is critical to creating and orchestrating an effective disaster response and recovery effort. The main goal of beAWARE is to provide support in all the phases of an emergency incident. More specifically, we propose an integrated solution to support forecasting, early warnings, transmission and routing of the emergency data, aggregated analysis of multimodal data and management the coordination between the first responders and the authorities. Our intention is to rely on platforms, theories and methodologies that are already used for disaster forecasting and management and add the elements that are necessary to make them working efficiently and in harm under the same objective. The overall context for beAWARE lies in the domain of situational awareness and command and control (C2). The first phase concerns the forecast of the extreme condition and the relevant preparations. Once a disaster occurs, an initial assessment needs to be conducted as soon as possible to determine the scope, geographical distribution, and scale of the incident. Situational awareness means being able to accurately determine what has happened, what is happening now, and what will come next, all in order to plan and coordinate the most effective response possible with the resources available. This observation phase will lead to an orientation phase suggesting both an individual as well as collective cognition orientation to data that is sensed and communicated. Once orientation to the data (or the lack of it) occurs then a decision is made, ultimately resulting is the final step, which is act. The crisis management center is always striving or struggling to gain a sense of what is reality to be able to feel that he or she can make a decision that is the best possible given the circumstances.
Costa A.,University Pompeu Fabra |
Costa A.,Catalan Institution for Research and Advanced Studies |
Sebastian-Galles N.,University Pompeu Fabra
Nature Reviews Neuroscience | Year: 2014
The ability to speak two languages often marvels monolinguals, although bilinguals report no difficulties in achieving this feat. Here, we examine how learning and using two languages affect language acquisition and processing as well as various aspects of cognition. We do so by addressing three main questions. First, how do infants who are exposed to two languages acquire them without apparent difficulty? Second, how does language processing differ between monolingual and bilingual adults? Last, what are the collateral effects of bilingualism on the executive control system across the lifespan? Research in all three areas has not only provided some fascinating insights into bilingualism but also revealed new issues related to brain plasticity and language learning. © 2014 Macmillan Publishers Limited. All rights reserved.
Dierssen M.,University Pompeu Fabra |
Dierssen M.,Research Center Biomedica En Red Of Enfermedades Raras Ciberer
Nature Reviews Neuroscience | Year: 2012
Down syndrome is the most common form of intellectual disability and results from one of the most complex genetic perturbations that is compatible with survival, trisomy 21. The study of brain dysfunction in this disorder has largely been based on a gene discovery approach, but we are now moving into an era of functional genome exploration, in which the effects of individual genes are being studied alongside the effects of deregulated non-coding genetic elements and epigenetic influences. Also, new data from functional neuroimaging studies are challenging our views of the cognitive phenotypes associated with Down syndrome and their pathophysiological correlates. These advances hold promise for the development of treatments for intellectual disability. © 2012 Macmillan Publishers Limited. All rights reserved.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 6.00M | Year: 2017
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies that target the pathobiology of cirrhosis. The objective of LIVERHOPE project is to evaluate a novel therapeutic strategy for patients with cirrhosis based on a combination of rifaximin and simvastatin, targeting the main pathophysiological mechanisms of disease progression , namely the impairment in the gut-liver axis and the persistent hepatic and systemic inflammatory response. This dual therapeutic approach is supported by preclinical data showing excellent and very promising results. We will perform two randomized double-blind trials to investigate safety, tolerability and efficacy of combination of simvastatin plus rifaximin in patients with decompensated cirrhosis in 5 EU countries (285 patients will be enrolled in two trials in DE, ES, FR, IT, UK). The expected impact is to halt progression to acute-on-chronic liver failure, the main cause of death, to decrease complications of the disease, to reduce hospital readmissions, to improve cost-effectiveness of therapy. Our final aim is to improve patients quality-of-life and increase survival as patients care is the core of LIVERHOPE. Within the project we will also investigate biomarkers of response to treatment and disease progression that can be useful in clinical practice for improving the treatment of patients. We will invest our effort also in communication and dissemination activities for increasing awareness about chronic liver diseases in European countries so that preventive measures can be established to decrease the burden of cirrhosis and reduce social stigmatization of patients with chronic liver diseases.